APO Research
Talk to an analyst

APO RESEARCH · REPORT

Duchenne Muscular Dystrophy

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Selected research

Market Outlook & Growth Opportunities

Global Duchenne Muscular Dystrophy Market Outlook and Growth Opportunities 2026

21 December 2025195 pages

Choose your research edition.

Industry ResearchDuchenne Muscular Dystrophy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Duchenne Muscular Dystrophy Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Duchenne Muscular Dystrophy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duchenne Muscular Dystrophy Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Duchenne Muscular Dystrophy Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.

North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.

Read the full market overview

In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

This report provides an overview of the global Duchenne Muscular Dystrophy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Duchenne Muscular Dystrophy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Duchenne Muscular Dystrophy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Duchenne Muscular Dystrophy market size, projected growth trends, production technologies, key applications, and end-use industries.

Duchenne Muscular Dystrophy Segment by Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy Segment by Type

Exondys 51

Emflaza

Translarna

Duchenne Muscular Dystrophy Segment by Application

Hospitals

Clinics

Home Care

Duchenne Muscular Dystrophy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Duchenne Muscular Dystrophy status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Duchenne Muscular Dystrophy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Duchenne Muscular Dystrophy significant trends, drivers, influence factors in global and regions.

6. To analyze Duchenne Muscular Dystrophy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Duchenne Muscular Dystrophy market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Duchenne Muscular Dystrophy industry.

Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Duchenne Muscular Dystrophy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Duchenne Muscular Dystrophy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Duchenne Muscular Dystrophy Industry Trends Table 2. Duchenne Muscular Dystrophy Industry Drivers Table 3. Duchenne Muscular Dystrophy Industry Opportunities and Challenges Table 4. Duchenne Muscular Dystrophy Industry Restraints Table 5. Global Duchenne Muscular Dystrophy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Duchenne Muscular Dystrophy Revenue Share by Company (2021-2026) Table 7. Global Duchenne Muscular Dystrophy Sales Volume by Company (K Doses) & (2021-2026) Table 8. Global Duchenne Muscular Dystrophy Sales Volume Share by Company (2021-2026) Table 9. Global Duchenne Muscular Dystrophy Average Price (USD/Dose) of Company (2021-2026) Table 10. Global Duchenne Muscular Dystrophy Company Ranking, (2024-2026) & (USD Million) Table 11. Global Duchenne Muscular Dystrophy Key Company Manufacturing Base & Headquarters Table 12. Global Duchenne Muscular Dystrophy Company, Product Type & Application Table 13. Global Duchenne Muscular Dystrophy Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Duchenne Muscular Dystrophy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Exondys 51 Table 18. Significant Companies of Emflaza Table 19. Significant Companies of Translarna Table 20. Global Duchenne Muscular Dystrophy Sales Volume by Type 2021 VS 2025 VS 2032 (K Doses) Table 21. Global Duchenne Muscular Dystrophy Sales Volume by Type (2021-2026) & (K Doses) Table 22. Global Duchenne Muscular Dystrophy Sales Volume by Type (2027-2032) & (K Doses) Table 23. Global Duchenne Muscular Dystrophy Sales Volume Share by Type (2021-2026) Table 24. Global Duchenne Muscular Dystrophy Sales Volume Share by Type (2027-2032) Table 25. Global Duchenne Muscular Dystrophy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Duchenne Muscular Dystrophy Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Duchenne Muscular Dystrophy Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Duchenne Muscular Dystrophy Sales Value Share by Type (2021-2026) Table 29. Global Duchenne Muscular Dystrophy Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Clinics Table 32. Significant Companies of Home Care Table 33. Global Duchenne Muscular Dystrophy Sales Volume by Application 2021 VS 2025 VS 2032 (K Doses) Table 34. Global Duchenne Muscular Dystrophy Sales Volume by Application (2021-2026) & (K Doses) Table 35. Global Duchenne Muscular Dystrophy Sales Volume by Application (2027-2032) & (K Doses) Table 36. Global Duchenne Muscular Dystrophy Sales Volume Share by Application (2021-2026) Table 37. Global Duchenne Muscular Dystrophy Sales Volume Share by Application (2027-2032) Table 38. Global Duchenne Muscular Dystrophy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Duchenne Muscular Dystrophy Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Duchenne Muscular Dystrophy Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Duchenne Muscular Dystrophy Sales Value Share by Application (2021-2026) Table 42. Global Duchenne Muscular Dystrophy Sales Value Share by Application (2027-2032) Table 43. Global Duchenne Muscular Dystrophy Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 44. Global Duchenne Muscular Dystrophy Sales by Region (2021-2026) & (K Doses) Table 45. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2021-2026) Table 46. Global Duchenne Muscular Dystrophy Sales by Region (2027-2032) & (K Doses) Table 47. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2027-2032) Table 48. Global Duchenne Muscular Dystrophy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Duchenne Muscular Dystrophy Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Duchenne Muscular Dystrophy Sales Value Share by Region (2021-2026) Table 51. Global Duchenne Muscular Dystrophy Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Duchenne Muscular Dystrophy Sales Value Share by Region (2027-2032) Table 53. Global Duchenne Muscular Dystrophy Market Average Price (USD/Dose) by Region (2021-2026) Table 54. Global Duchenne Muscular Dystrophy Market Average Price (USD/Dose) by Region (2027-2032) Table 55. Global Duchenne Muscular Dystrophy Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Table 56. Global Duchenne Muscular Dystrophy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 58. Global Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2026) Table 59. Global Duchenne Muscular Dystrophy Sales by Country (2027-2032) & (K Doses) Table 60. Global Duchenne Muscular Dystrophy Sales Market Share by Country (2027-2032) Table 61. Global Duchenne Muscular Dystrophy Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Duchenne Muscular Dystrophy Sales Value Market Share by Country (2021-2026) Table 63. Global Duchenne Muscular Dystrophy Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Duchenne Muscular Dystrophy Sales Value Market Share by Country (2027-2032) Table 65. Sarepta Therapeutics Company Information Table 66. Sarepta Therapeutics Business Overview Table 67. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 68. Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio Table 69. Sarepta Therapeutics Recent Development Table 70. PTC Therapeutics Company Information Table 71. PTC Therapeutics Business Overview Table 72. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 73. PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio Table 74. PTC Therapeutics Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 78. Pfizer Duchenne Muscular Dystrophy Product Portfolio Table 79. Pfizer Recent Development Table 80. Bristol-Myers Squibb Company Information Table 81. Bristol-Myers Squibb Business Overview Table 82. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 83. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio Table 84. Bristol-Myers Squibb Recent Development Table 85. Italfarmaco Company Information Table 86. Italfarmaco Business Overview Table 87. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 88. Italfarmaco Duchenne Muscular Dystrophy Product Portfolio Table 89. Italfarmaco Recent Development Table 90. Santhera Pharmaceuticals Company Information Table 91. Santhera Pharmaceuticals Business Overview Table 92. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 93. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio Table 94. Santhera Pharmaceuticals Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Duchenne Muscular Dystrophy Distributors List Table 98. Duchenne Muscular Dystrophy Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Duchenne Muscular Dystrophy Product Image Figure 2. Global Duchenne Muscular Dystrophy Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Duchenne Muscular Dystrophy Sales Value (2021-2032) & (US$ Million) Figure 4. Global Duchenne Muscular Dystrophy Sales (2021-2032) & (K Doses) Figure 5. Global Duchenne Muscular Dystrophy Sales Average Price (USD/Dose) & (2021-2032) Figure 6. Global Duchenne Muscular Dystrophy Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Exondys 51 Image Figure 10. Emflaza Image Figure 11. Translarna Image Figure 12. Global Duchenne Muscular Dystrophy Sales Volume by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 13. Global Duchenne Muscular Dystrophy Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Duchenne Muscular Dystrophy Sales Volume Share by Type (2021-2032) Figure 15. Global Duchenne Muscular Dystrophy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Duchenne Muscular Dystrophy Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Duchenne Muscular Dystrophy Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Home Care Image Figure 21. Global Duchenne Muscular Dystrophy Sales Volume by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 22. Global Duchenne Muscular Dystrophy Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Duchenne Muscular Dystrophy Sales Volume Share by Application (2021-2032) Figure 24. Global Duchenne Muscular Dystrophy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Duchenne Muscular Dystrophy Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Duchenne Muscular Dystrophy Sales Value Share by Application (2021-2032) Figure 27. Global Duchenne Muscular Dystrophy Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 28. Global Duchenne Muscular Dystrophy Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Duchenne Muscular Dystrophy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Duchenne Muscular Dystrophy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Duchenne Muscular Dystrophy Sales Value (2021-2032) & (US$ Million) Figure 32. North America Duchenne Muscular Dystrophy Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Duchenne Muscular Dystrophy Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Duchenne Muscular Dystrophy Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Duchenne Muscular Dystrophy Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Duchenne Muscular Dystrophy Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Duchenne Muscular Dystrophy Sales Value (2021-2032) & (US$ Million) Figure 38. South America Duchenne Muscular Dystrophy Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Duchenne Muscular Dystrophy Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Duchenne Muscular Dystrophy Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Duchenne Muscular Dystrophy Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Duchenne Muscular Dystrophy Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Exondys 51
  • Emflaza
  • Translarna
Applications
  • Hospitals
  • Clinics
  • Home Care
Companies covered
  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Duchenne Muscular Dystrophy Sales Value (2021-2032)
  4. 1.2.2 Global Duchenne Muscular Dystrophy Sales Volume (2021-2032)
  5. 1.2.3 Global Duchenne Muscular Dystrophy Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Duchenne Muscular Dystrophy Market Dynamics
  1. 2.1 Duchenne Muscular Dystrophy Industry Trends
  2. 2.2 Duchenne Muscular Dystrophy Industry Drivers
  3. 2.3 Duchenne Muscular Dystrophy Industry Opportunities and Challenges
  4. 2.4 Duchenne Muscular Dystrophy Industry Restraints
3 Duchenne Muscular Dystrophy Market by Company
  1. 3.1 Global Duchenne Muscular Dystrophy Company Revenue Ranking in 2025
  2. 3.2 Global Duchenne Muscular Dystrophy Revenue by Company (2021-2026)
  3. 3.3 Global Duchenne Muscular Dystrophy Sales Volume by Company (2021-2026)
  4. 3.4 Global Duchenne Muscular Dystrophy Average Price by Company (2021-2026)
  5. 3.5 Global Duchenne Muscular Dystrophy Company Ranking (2024-2026)
  6. 3.6 Global Duchenne Muscular Dystrophy Company Manufacturing Base and Headquarters
  7. 3.7 Global Duchenne Muscular Dystrophy Company Product Type and Application
  8. 3.8 Global Duchenne Muscular Dystrophy Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Duchenne Muscular Dystrophy Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Duchenne Muscular Dystrophy Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Duchenne Muscular Dystrophy Market by Type
  1. 4.1 Duchenne Muscular Dystrophy Type Introduction
  2. 4.1.1 Exondys 51
  3. 4.1.2 Emflaza
  4. 4.1.3 Translarna
  5. 4.2 Global Duchenne Muscular Dystrophy Sales Volume by Type
  6. 4.2.1 Global Duchenne Muscular Dystrophy Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Duchenne Muscular Dystrophy Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Duchenne Muscular Dystrophy Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Duchenne Muscular Dystrophy Sales Value by Type
  10. 4.3.1 Global Duchenne Muscular Dystrophy Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Duchenne Muscular Dystrophy Sales Value by Type (2021-2032)
  12. 4.3.3 Global Duchenne Muscular Dystrophy Sales Value Share by Type (2021-2032)
5 Duchenne Muscular Dystrophy Market by Application
  1. 5.1 Duchenne Muscular Dystrophy Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Home Care
  5. 5.2 Global Duchenne Muscular Dystrophy Sales Volume by Application
  6. 5.2.1 Global Duchenne Muscular Dystrophy Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Duchenne Muscular Dystrophy Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Duchenne Muscular Dystrophy Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Duchenne Muscular Dystrophy Sales Value by Application
  10. 5.3.1 Global Duchenne Muscular Dystrophy Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Duchenne Muscular Dystrophy Sales Value by Application (2021-2032)
  12. 5.3.3 Global Duchenne Muscular Dystrophy Sales Value Share by Application (2021-2032)
6 Duchenne Muscular Dystrophy Regional Sales and Value Analysis
  1. 6.1 Global Duchenne Muscular Dystrophy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Duchenne Muscular Dystrophy Sales by Region (2021-2032)
  3. 6.2.1 Global Duchenne Muscular Dystrophy Sales by Region: 2021-2026
  4. 6.2.2 Global Duchenne Muscular Dystrophy Sales by Region (2027-2032)
  5. 6.3 Global Duchenne Muscular Dystrophy Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Duchenne Muscular Dystrophy Sales Value by Region (2021-2032)
  7. 6.4.1 Global Duchenne Muscular Dystrophy Sales Value by Region: 2021-2026
  8. 6.4.2 Global Duchenne Muscular Dystrophy Sales Value by Region (2027-2032)
  9. 6.5 Global Duchenne Muscular Dystrophy Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Duchenne Muscular Dystrophy Sales Value (2021-2032)
  12. 6.6.2 North America Duchenne Muscular Dystrophy Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Duchenne Muscular Dystrophy Sales Value (2021-2032)
  15. 6.7.2 Europe Duchenne Muscular Dystrophy Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Duchenne Muscular Dystrophy Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Duchenne Muscular Dystrophy Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Duchenne Muscular Dystrophy Sales Value (2021-2032)
  21. 6.9.2 South America Duchenne Muscular Dystrophy Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Duchenne Muscular Dystrophy Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Duchenne Muscular Dystrophy Sales Value Share by Country, 2025 VS 2032
7 Duchenne Muscular Dystrophy Country-level Sales and Value Analysis
  1. 7.1 Global Duchenne Muscular Dystrophy Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Duchenne Muscular Dystrophy Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Duchenne Muscular Dystrophy Sales by Country (2021-2032)
  4. 7.3.1 Global Duchenne Muscular Dystrophy Sales by Country (2021-2026)
  5. 7.3.2 Global Duchenne Muscular Dystrophy Sales by Country (2027-2032)
  6. 7.4 Global Duchenne Muscular Dystrophy Sales Value by Country (2021-2032)
  7. 7.4.1 Global Duchenne Muscular Dystrophy Sales Value by Country (2021-2026)
  8. 7.4.2 Global Duchenne Muscular Dystrophy Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Duchenne Muscular Dystrophy Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Duchenne Muscular Dystrophy Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Duchenne Muscular Dystrophy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sarepta Therapeutics
  2. 8.1.1 Sarepta Therapeutics Company Information
  3. 8.1.2 Sarepta Therapeutics Business Overview
  4. 8.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
  6. 8.1.5 Sarepta Therapeutics Recent Developments
  7. 8.2 PTC Therapeutics
  8. 8.2.1 PTC Therapeutics Company Information
  9. 8.2.2 PTC Therapeutics Business Overview
  10. 8.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
  12. 8.2.5 PTC Therapeutics Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Duchenne Muscular Dystrophy Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Italfarmaco
  26. 8.5.1 Italfarmaco Company Information
  27. 8.5.2 Italfarmaco Business Overview
  28. 8.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Italfarmaco Duchenne Muscular Dystrophy Product Portfolio
  30. 8.5.5 Italfarmaco Recent Developments
  31. 8.6 Santhera Pharmaceuticals
  32. 8.6.1 Santhera Pharmaceuticals Company Information
  33. 8.6.2 Santhera Pharmaceuticals Business Overview
  34. 8.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
  36. 8.6.5 Santhera Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Duchenne Muscular Dystrophy Value Chain Analysis
  2. 9.1.1 Duchenne Muscular Dystrophy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Duchenne Muscular Dystrophy Sales Mode & Process
  6. 9.2 Duchenne Muscular Dystrophy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Duchenne Muscular Dystrophy Distributors
  9. 9.2.3 Duchenne Muscular Dystrophy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst